Johnson & Johnson's Q2 2016 earnings call shows strong performance across all segments, exceeding analyst expectations.  Management highlighted robust pharmaceutical growth, particularly in oncology and immunology, coupled with positive operational sales growth in Consumer and Medical Devices.  The call highlights improving margins in Consumer, a strong pipeline in pharmaceuticals, and a focus on driving growth and efficiency in Medical Devices.  This suggests likely continued positive stock price momentum in the next few weeks.
[1]
